The investment bank UBS recently reached more muted conclusions, noting that generative AI would represent more of an evolution than a revolution for biopharma.
Conversely, McKinsey bets the technology could deliver productivity gains that account for 10% to 15% of overall R&D costs. This potential largely stems from the applicatio…